You searched for Antibody candidate - Page 19 of 69

News and Trends 6 Jul 2017

Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II

Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in…

July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 26 Jul 2024

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies

…GLP1R antibodies. One notable candidate, TB59-2, has shown strong preclinical efficacy in controlling blood glucose levels with a favorable pharmacokinetic profile. Another candidate, TB01-3, demonstrated effective blood glucose regulation in…

July 26, 2024 - 8 minutesmins - By Jules Adam

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets…

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

…drug-to-antibody ratio as well as the linker chemistry of the ADC,” said Schumacher. For example, ADCs with very toxic payloads should pack fewer molecules per antibody, whereas candidates with milder…

May 3, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Jan 2023

Hummingbird Bioscience and Synaffix to develop ADC program

Synaffix B.V. and Hummingbird Bioscience have entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation antibody drug conjugate (ADC) program using Synaffix technology. Synaffix…

January 5, 2023 - 3 minutesmins - By Jim Cornall

In Depth 17 Oct 2017

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

…series of phase III trials with the antibody for psoriatic arthritis, as well as another head-to-head study with the anti-IL-17 antibody, Cosentyx. Boehringer Ingelheim and AbbVie have partnered to develop…

October 17, 2017 - 7 minutesmins - By Diana Kwon

In Depth 2 Apr 2025

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

…the amyloid-plaques-targeting antibody showed some plaque clearance, the cognitive data were mixed at best. Then came Leqembi in 2023. This second-generation amyloid-targeting antibody showed a modest but statistically significant slowing…

April 2, 2025 - 10 minutesmins - By Jules Adam

In Depth 9 Aug 2023

Meet the startup working to help treat a rare pediatric cancer

…– a central process in the immune system – thereby minimizing pain caused by the antibody binding to peripheral nerves. This, in turn, enables higher antibody dosing. To add to…

August 9, 2023 - 7 minutesmins - By Roohi Mariam Peter

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

…returned encouraging data. Biogen’s antibody candidate aducanumab also targets Aβ aggregation and is also currently being evaluated in two large-scale Phase III trials. Even with the recent disappointing results of…

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

CatalYm’s monoclonal antibody visugromab bags $150M

News and Trends 16 Jul 2024

German biotech raises $150M on its way to tackle cancer therapy resistance

…Gilde Healthcare. CatalYm is a Munich-based biotech company, with a novel approach to tackle cancer resistance through its lead candidate, visugromab. This humanized monoclonal antibody targets the tumor-produced growth differentiation…

July 16, 2024 - 9 minutesmins - By Jules Adam

Interview 16 Nov 2017

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

…of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates to control the immune system,…

November 16, 2017 - 6 minutesmins - By Alex Dale

Best in Biotech 19 Sep 2024

Six immunology biotech companies revolutionizing immune treatments in 2024

…mast cells. This candidate will be trialed to treat chronic inducible urticaria. Meanwhile, the company’s second candidate is called SAB03, which agonizes PD-1, a clinically validated target in rheumatoid arthritis,…

September 19, 2024 - 7 minutesmins - By Willow Shah-Neville

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Antibody candidate

Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II

Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Tubulis Rides Investment Wave in ADCs with €60M Series B

Hummingbird Bioscience and Synaffix to develop ADC program

Blockbuster Potential: How Biotech is Paving the Way to Clear Skin from Psoriasis

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Meet the startup working to help treat a rare pediatric cancer

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

German biotech raises $150M on its way to tackle cancer therapy resistance

Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Six immunology biotech companies revolutionizing immune treatments in 2024

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!